Thompson Rahsaan sold $475K of ZVRA
Thompson Rahsaan (Chief Legal & Compliance) sold 42,666 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.13 ($0.47M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the reported sale size, price, and post-transaction holdings, but the presence of a 10b5-1 plan reduces interpretive weight for near-term trading decisions.
Market read
Traders may note insider selling, but the pre-arranged 10b5-1 structure and lack of fundamental updates make this more of a monitoring item than a catalyst.
What to watch
The filing does not disclose reasons for the sale, and it lacks any concurrent company-specific catalyst (trial, financing, partnership, or regulatory event).
Background
This is an SEC Form 4 insider transaction disclosure for ZEVRA THERAPEUTICS, INC. (ZVRA).
Ticker impact
Zevra Therapeutics disclosed an insider open-market sale by its Chief Legal & Compliance officer: 42,666 shares sold at $11.1277 on 2026-08-14.
Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.
The article provides only an insider sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, operational update, or enforcement/regulatory action.
Market effects
No sector read-through is provided beyond a single-company insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerZEVRA THERAPEUTICS, INC.
Subject of the Form 4 insider transaction disclosure.
- insiderThompson Rahsaan
Chief Legal & Compliance officer who sold shares in an open-market transaction under a 10b5-1 plan.
